Since therapy-resistant PCa tumours are linked to aggressive forms of the disease with high mortality rates, it is critical to understand the molecular mechanisms of AR activation through antagonistic to agonistic switch [27,28]. The gene discussed is AR; the disease is posterior cortical atrophy.